Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Memory Impairment-Pipeline Review, H1 2015

Memory Impairment-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Memory Impairment-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Memory Impairment-Pipeline Review, H1 2015', provides an overview of the Memory Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Memory Impairment

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Memory Impairment

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Memory Impairment Overview 8

Therapeutics Development 9

Pipeline Products for Memory Impairment-Overview 9

Pipeline Products for Memory Impairment-Comparative Analysis 10

Memory Impairment-Therapeutics under Development by Companies 11

Memory Impairment-Therapeutics under Investigation by Universities/Institutes 12

Memory Impairment-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Memory Impairment-Products under Development by Companies 15

Memory Impairment-Products under Investigation by Universities/Institutes 17

Memory Impairment-Companies Involved in Therapeutics Development 18

Calico LLC 18

Dart NeuroScience LLC 19

M et P Pharma AG 20

Neuren Pharmaceuticals Limited 21

Omeros Corporation 22

Pharnext SAS 23

Sunovion Pharmaceuticals Inc. 24

Takeda Pharmaceutical Company Limited 25

Memory Impairment-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

2-PMPA-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AC-253-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Antisense Oligonucleotide to Inhibit microRNA for Neurology-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

dehydroevodiamine hydrochloride-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drug for Memory Impairment-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

HT-0712-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

HT-3951-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NNZ-2591-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

P7-C3A20-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

pregnenolone succinate-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

PXT-864-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

roflumilast-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecule 1 to Inhibit PDE4 for Memory Impairment-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecule 2 to Inhibit PDE4 for Memory Impairment-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecule to Activate LPL for CNS and Metabolic Disorders-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecule to Inhibit MAO-B for Memory Impairment-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules to Activate Carbonic Anhydrase for Learning and Memory Impairment-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules to Activate NAMPT for Neurological Disorders-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Activate PKC for CNS and Oncology-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules to Antagonize GALR3 for Memory Impairment-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Stem Cell Therapy for Memory Impairment and Brain Diseases-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Memory Impairment-Recent Pipeline Updates 64

Memory Impairment-Dormant Projects 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

Number of Products under Development for Memory Impairment, H1 2015 9

Number of Products under Development for Memory Impairment-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Development by Companies, H1 2015 (Contd..1) 16

Products under Investigation by Universities/Institutes, H1 2015 17

Memory Impairment-Pipeline by Calico LLC, H1 2015 18

Memory Impairment-Pipeline by Dart NeuroScience LLC, H1 2015 19

Memory Impairment-Pipeline by M et P Pharma AG, H1 2015 20

Memory Impairment-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 21

Memory Impairment-Pipeline by Omeros Corporation, H1 2015 22

Memory Impairment-Pipeline by Pharnext SAS, H1 2015 23

Memory Impairment-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 24

Memory Impairment-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Stage and Target, H1 2015 28

Number of Products by Stage and Mechanism of Action, H1 2015 30

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 34

Memory Impairment Therapeutics-Recent Pipeline Updates, H1 2015 64

Memory Impairment-Dormant Projects, H1 2015 67

Memory Impairment-Dormant Projects (Contd..1), H1 2015 68

List of Figures

Number of Products under Development for Memory Impairment, H1 2015 9

Number of Products under Development for Memory Impairment-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 27

Number of Products by Stage and Top 10 Targets, H1 2015 27

Number of Products by Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 33

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Calico LLC

Dart NeuroScience LLC

M et P Pharma AG

Neuren Pharmaceuticals Limited

Omeros Corporation

Pharnext SAS

Sunovion Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited

Memory Impairment Therapeutic Products under Development, Key Players in Memory Impairment Therapeutics, Memory Impairment Pipeline Overview, Memory Impairment Pipeline, Memory Impairment Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com